Ahmed Youssef

💥 𝗕𝗶𝗴 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀! 💥 Polpharma Biologics 🤝 MS PHARMA are teaming up to bring three cutting-edge biosimilars — Vedolizumab, Ocrelizumab & Guselkumab — to patients across the MENA region. ✅ World-class development & manufacturing ✅ Localized production in Saudi Arabia ✅ Greater access to life-changing treatments This is more than a deal — it’s a step toward making advanced biologics accessible and affordable for more patients than ever before. 🌍💉 The future of healthcare is being built today. #Biosimilars #HealthcareInnovation #Partnerships #MENA

288

4 Kommentare

As part of EVA Pharma’s strategy to deepen reliance on local suppliers and manufacturers, we have signed a strategic contract with the “NCMP” company. This collaboration aims to strengthen local sourcing and reduce emissions by adopting and innovating new approaches that transform the supply chain into a more sustainable and localized model.  #EVAPharma #Pharmaconex 

106

1 Kommentar

Amman Pharmaceutical Industries (API) is committed to expanding patient access to affordable, high-quality medicines on a global scale. In 2023, we collaborated with USP -an independent, scientific nonprofit organization that develops public quality standards for medicines, dietary supplements, and food ingredients- to donate analytical methods and expertise. API donated scientific methods and specifications, based on which USP created related monograph. The monograph is currently under review and is expected to be published before the end of this year. “Through this collaboration with USP, our contribution will help inform the development of public quality standards. Amman Pharmaceutical Industries is proud to support USP and its mission to advance quality standards and solutions that increase the availability of medicines, protect patient safety, and enhance global health” said Dr. Fadi Atrash, CEO of API. This donation followed a meeting with Ronald T. Piervincenzi, USP CEO, during his 2023 visit to Jordan, which was kindly facilitated by Dr. Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers (JAPM), which has been instrumental in helping USP achieve its goals in the region. Dr. Sboul commented that “JAPM is proud of API’s contribution to USP’s legacy of quality that continues to thrive. Hanan Sboul #JAPM #USP #AmmanPharma

133

3 Kommentare

Sandoz the global leader in generic and biosimilar medicines, today announced the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone for the treatment of short stature to the Egyptian market, as part of its ongoing efforts to support Egypt’s Vision 2030. “In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome. The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.” Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said. “Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role.” "As noted, short stature affects children and adolescents, not only physically but also psychologically" Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, said. “Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results,” "The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development," Sameh Elbagoury, Sandoz Egypt Country Head, said. “Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15 mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature,” #PaediatricEndocrinology #Biosimilars #GrowthHormone #OMNITROPE #PublicHealth #SandozEgypt #Sandoz #PioneeringAccessForPatients

349

5 Kommentare